Painful diabetic neuropathy (PDN) is a long-term complication of diabetes. Defining symptoms include mechanical allodynia (pain due to light pressure or touch) and morphine hyposensitivity. In our previous work using the streptozotocin (STZ)-diabetic rat model of PDN, morphine hyposensitivity developed in a temporal manner with efficacy abolished at 3 months post-STZ and maintained for 6 months post-STZ. As this time course mimicked that for the temporal development of hyposensitivity to the pain-relieving effects of the furoxan nitric oxide (NO) donor, PRG150 (3-methylfurox an-4-carbaldehyde) in STZ-diabetic rats, we hypothesized that progressive depletion of endogenous NO bioactivity may underpin the temporal loss of morphine sensitivity in STZ-diabetic rats. Furthermore, we hypothesized that replenishment of NO bioactivity may restore morphine sensitivity in these animals. Diabetes was induced in male Dark Agouti rats by intravenous injection of STZ (85 mg/kg). Diabetes was confirmed on day 7 if blood glucose concentrations were ≥15 mmol/L. Mechanical allodynia was fully developed in the bilateral hindpaws by 3 weeks of STZ-diabetes in rats and this was maintained for the study duration. Morphine hyposensitivity developed in a temporal manner with efficacy abolished by 3 months post-STZ. Administration of dietary l-arginine (NO precursor) at 1 g/d to STZ-diabetic rats according to a 15-week prevention protocol initiated at 9 weeks post-STZ prevented abolition of morphine efficacy. When given as an 8-week intervention protocol in rats where morphine efficacy was abolished, dietary l-arginine at 1 g/d progressively rescued morphine efficacy and potency. Our findings implicate NO depletion in the development of morphine hyposensitivity in STZ-diabetic rats.
developed in a temporal manner and was fully developed by approximately 3 months of diabetes with it being maintained for at least 6 months. [4] [5] [6] Interestingly, this time course mimicked that for progressive development of hyposensitivity to the pain-relieving effects of the furoxan NO donor, PRG150, in STZ-diabetic rats 3 as well as clinical reports of the ineffectiveness of morphine for the symptomatic relief of PDN. 1, 2 Together, our previous findings suggest that temporal depletion of NO bioactivity in advanced diabetes may have a key role in the pathobiology of the associated morphine hyposensitivity.
Endogenous NO is synthesized from the precursor, l-arginine, by 3 NO synthase (NOS) enzymes, viz endothelial NOS, neuronal NOS and inducible NOS. 7 Under normal conditions in vivo, NO is a highly diffusible gas with a half-life of only a few seconds that regulates many physiological processes. 7 However, after peripheral nerve injury, ongoing ectopic firing of injured primary afferents induces central sensitization in the dorsal horn of the spinal cord that is underpinned by persistent activation of the N-methyl-d-aspartate (NMDA)/NOS/NO signaling cascade and glial cell activation, to markedly increase NO formation at multiple levels of the somatosensory nervous system.
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In diabetes, there is increased generation of superoxide that reacts with elevated levels of NO to increase formation of the neurotoxin, peroxynitrite, resulting in nitrooxidative stress and the development of PDN. 11, 12 From the foregoing, we developed the hypothesis that progressive depletion of endogenous NO bioactivity may have a key role in the temporal development of morphine hyposensitivity in STZ-diabetic rats and that replenishment of endogenous NO bioactivity may restore morphine sensitivity in these animals.
To test our hypothesis, STZ-diabetic rats were administered di- 
| RESULTS

| Mechanical hypersensitivity in the hindpaws of STZ-diabetic rats
The mean (± SEM) paw withdrawal thresholds (PWTs) in the bilateral hindpaws of drug-naïve STZ-diabetic Dark Agouti (DA) rats were significantly lower (P ≤ .05) than those for control nondiabetic rats (11.9 ± 0.2 g). Specifically, in Group 1 STZ-diabetic DA rats (Figure 1 ), the mean (±SEM) PWTs decreased significantly (F (3, 71) = 265.4, P ≤ .05; one-way ANOVA with Tukey's multiple comparisons test) from 11.9 (± 0.2) g in non-diabetic rats to 6.8 (± 0.3) g by 9 weeks post-STZ administration. In Group 2 STZ-diabetic rats (Figure 1 ), the mean (± SEM) hindpaw PWTs at 14 and 24 weeks post-STZ administration were significantly reduced (F (2,11) = 14.6, (P ≤ .05) one-way ANOVA with Tukey's multiple comparisons test) to 3.8 (± 0.2) g and 3.1 (± 0.3) g respectively. These data show that mechanical allodynia was fully developed (PWTs ≤ 6 g) for at least 24 weeks post-STZ administration. In Group 3 rats (Figure 1 ), the mean (± SEM) hindpaw PWT at 24 weeks post-STZ administration was 3.1 (± 0.1) g which differed significantly (P > .05; unpaired t test) from that in non-diabetic rats at 11.9 (± 0.2) g. Overall, dietary l-arginine treatment of STZ-diabetic rats for up to 15 weeks did not reverse mechanical allodynia in the bilateral hindpaws (see details in
Supplementary Results).
F I G U R E 1 Schematic diagram of the 3 l-arginine dosing protocols used in the present work 2.2 | Dietary l-arginine prevents loss of morphine efficacy in STZ-diabetic rats
| Group 1: l-arginine prevention protocol
The dose-response curve for single subcutaneous (s.c.) bolus doses of morphine in STZ-diabetic DA rats at 9 weeks post-STZ administration is shown in Figure 2 . The corresponding mean (± SEM) dose that produced a 50% response (ED 50 ) was 6.1 (± 0.3) mg/kg in agreement with that for STZ-diabetic DA rats at 3 weeks post-STZ reported previously by our laboratory. 4 Additionally, the mean (± SEM) ED 50 for s.c. morphine (7.0 ± 0.5 mg/kg) after 3 weeks of comparison test) from that for s.c. morphine at 6.1 mg/kg in opioidnaïve non-diabetic control rats (136.9 ± 16.1%MPE.h).
| Group 3: l-arginine late intervention protocol
In STZ-diabetic DA rats where morphine efficacy had been abolished 
| Dietary l-arginine: No effect on morphine efficacy or potency in control non-diabetic rats
Mean (± SEM) food intake for l-arginine treated STZ-diabetic rats was 43.2 (± 0.2) g/d whereas control non-diabetic rats treated with dietary l-arginine consumed 20.5 (± 0.7) g of food per day. Thus, in order to give comparable doses of l-arginine to both STZ-diabetic and nondiabetic weight-matched control rats, the concentration of l-arginine in the ground rodent chow was 2-fold higher for non-diabetic rats at 5% c.f. 2.5% for STZ-diabetic animals. For non-diabetic male DA rats, the mean (± SEM) ED 50 at 3.0 (± 0.2 mg/kg) for the antinociception (%MPE) dose-response curve ( Figure 5 ) evoked by single s.c.
bolus doses of morphine did not differ significantly (P > .05; unpaired t test) from that (2.5 ± 0.2 mg/kg) for non-diabetic male DA rats admin- 
| General health
Following induction of diabetes with STZ, there was a 12%-13% de- However, NO formed from the dietary l-arginine, may have attenuated perineurial hypoxia and the associated oxidative stress, as well as reducing otherwise elevated levels of diacylglycerol and activated protein kinase C (PKC), that are produced as a consequence of persistent hyperglycaemia in diabetes. 14, 15 Of particular importance to the present work, PKC mechanisms are implicated in desensitization of the opioid receptor [16] [17] [18] [19] [20] [21] [22] as well as the development of diabetic complications. 16 A role for PKC in the development of opioid hyposensitivity in diabetes is supported by observation that supraspinal pretreatment of STZ-diabetic rats with the PKC inhibitor, calphostin C, prevented the development of opioid hyposensitivity. 23, 24 In recent work by others in STZ-diabetic rats exhibiting opioid hyposensitivity, MOP receptor immunoreactive primary sensory neurons were co-localized with activated PKC isoforms as well as with the receptor for advanced glycation end products (RAGE). 16 Using a range of measures including administration of a selective PKC inhibitor, intrathecal RAGE siRNA, or inhibition of advanced glycation end product (AGE) formation to prevent both RAGE-dependent PKC activation and desensitization of the MOP receptor, opioid analgesic efficacy was restored. 16 In other work in rats with advanced diabetes at 12 weeks post-STZ, the inhibitory effects of intraplantar bolus doses of morphine on capsaicin-induced nocifensive behaviour were impaired. 25 Also, there was a markedly reduced inhibitory effect of morphine on capsaicin-induced TRPV1 current in DRG neurons from these animals. 25 These changes were associated with a loss of func- rats. 28 This difference may be because l-arginine treatment commenced at the time of diabetes onset rather than at 9, 14 or 30 weeks post-STZ administration as was done in the present work.
As l-arginine has the potential to stimulate hormonal secretion including that of growth hormone, glucagon, prolactin and insulin, 29 we assessed the effect of chronic dietary l-arginine on blood glucose levels in rats with advanced STZ-induced diabetes. Importantly, we show that irrespective of when the dietary l-arginine intervention was initiated in the interval 9-30 weeks post-STZ administration, it did not alter the markedly elevated blood glucose levels (>20 mmol/L) in these animals (Supplementary Results). Our findings are aligned with other work whereby intravenous injection of a bolus dose of l-arginine (150 mg/ kg) followed by chronic infusion (10 mg/kg per minute for 60 minutes), did not significantly alter (P > .05) blood glucose levels in either nondiabetic or STZ-diabetic rats. 30 Furthermore, chronic l-arginine administration in the drinking water at 1.25 mg/mL for 4 weeks commencing at 12 weeks post-STZ administration or at 1.0 mg/mL for 12 weeks after diabetes induction 31, 32 did not significantly alter (P > .05) hyperglycaemia in these animals, mirroring the profoundly elevated blood glucose levels measured in STZ-diabetic rats herein.
Irrespective of the cellular mechanisms involved in the restoration of morphine efficacy in rats with advanced STZ-diabetes and given di- 
| MATERIALS AND METHODS
| In vivo experimentation
| Animals
Ethics approval was from the Animal Ethics Committee of The University of Queensland (Brisbane, Australia). Male DA rats were purchased from the Central Animal Breeding House, The University of Queensland. Rats were housed in pairs in a temperature controlled room (21 ± 2°C; mean ± SD) with a 12 h/12 h light/dark cycle. Rats had free access to rodent chow and water, and were acclimatized prior to initiation of experimentation.
| Reagents and materials
l-arginine hydrochloride, streptozotocin, citric acid and trisodium citrate were from Sigma Aldrich (Sydney, Australia). (Brisbane, Australia).
| Induction of diabetes with Streptozotocin (STZ)
Anaesthesia was induced with a mixture of ketamine (100 mg/kg, ip) and xylazine (16 mg/kg, ip) to facilitate insertion of a polyethylene cannula (pre-filled with 0.1 mL of sterile saline) into the right common jugular vein. Cannulae were tested for correct placement by withdrawing a small amount of blood. Diabetes was induced in rats by injection of STZ (85 mg/kg in 0.1 mol/L citrate buffer at pH 4.5) via the jugular vein cannula. [3] [4] [5] Benzylpenicillin (60 mg s.c.) was administered and rats were monitored during surgical recovery. Diabetes was confirmed on day 7 post-STZ in individual rats if daily water intake was ≥100 mL and blood glucose levels (BGLs) were ≥15 mmol/L. Nondiabetic rats were used in the control experiments.
| l-arginine dietary administration
A group of control non-diabetic rats received dietary l-arginine at 
| Dosing solutions and dose administration
| Treatment groups
This study comprised 3 groups of STZ-diabetic DA rats and 1 group of non-diabetic DA rats. Morphine bolus dose administration was according to a "washout" protocol with 4 days of washout between successive doses and each rat received a maximum of 3 doses. 
| Group 3 STZ-diabetic rats: l-arginine late intervention protocol
Group 3 STZ-diabetic DA rats (n = 6, 228.8 ± 4.2 g, mean ± SEM)
were a sub-group of the same rats used by Nielsen et al. 
| Control non-diabetic rats
A group of opioid-naïve, non-diabetic DA rats (n = 18; 215.0 ± 2.0 g, mean ± SEM) received one of three bolus doses (Figure 4 ) of s.c.
morphine. PWTs were measured in the bilateral hindpaws at regular intervals over a 3-hour post-dosing period. Opioid-naïve control DA rats that had received dietary l-arginine at 1 g/d mixed in ground rodent chow for 1-week (n = 18; 236.8 ± 2.5 g, mean ± SEM) also received a single s.c. bolus dose of morphine and underwent antinociceptive testing ( Figure 4 ). As STZ-diabetic rats eat twice as much as non-diabetic rats, the concentration of l-arginine mixed with ground rodent chow administered to control non-diabetic rats was doubled to 5% to ensure that l-arginine intake was similar between STZ-diabetic rats and the control non-diabetic rats.
| Assessment of paw withdrawal thresholds in the bilateral hindpaws
Mechanical allodynia in the bilateral hindpaws, a defining symptom of neuropathic pain, was assessed using calibrated Von 
| Data analysis
The Von Frey scores for individual rats were converted to the percentage of the Maximum Possible Effect (%MPE), using the following formula:
where maximum threshold = 20 g.
%MPE vs time curves were constructed for individual rats. The area under the %MPE vs time curve (%MPE AUC value; %MPE.h) was calculated using trapezoidal integration. The mean (± SEM) percentage maximum AUC (%Max AUC) for each morphine dose was plotted vs the log dose to produce dose-response curves. ED 50 doses (mean ± SEM) were estimated using non-linear regression of the %Max AUC vs log dose values as implemented in the GraphPad Prism (v 6.0) statistical analysis package. 
| Statistical analysis
